Equity Overview
Price & Market Data
Price: $1.78
Daily Change: -$0.10 / 5.62%
Daily Range: $1.78 - $2.12
Market Cap: $168,338,320
Daily Volume: 1,138,189
Performance Metrics
1 Week: -10.84%
1 Month: 3.43%
3 Months: 138.2%
6 Months: 23.97%
1 Year: -7.42%
YTD: 13.84%
Company Details
Employees: 147
Sector: Health technology
Industry: Biotechnology
Country:
Details
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.